1. Home
  2. PHOS vs ANTX Comparison

PHOS vs ANTX Comparison

Compare PHOS & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Phosphate Corp. American Depositary Shares

PHOS

First Phosphate Corp. American Depositary Shares

SELL

Current Price

$10.84

Market Cap

211.3M

Sector

Industrials

ML Signal

SELL

Logo AN2 Therapeutics Inc.

ANTX

AN2 Therapeutics Inc.

SELL

Current Price

$4.39

Market Cap

172.9M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PHOS
ANTX
Founded
2006
2017
Country
Canada
United States
Employees
N/A
N/A
Industry
Mining & Quarrying of Nonmetallic Minerals (No Fuels)
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
211.3M
172.9M
IPO Year
2010
2022

Fundamental Metrics

Financial Performance
Metric
PHOS
ANTX
Price
$10.84
$4.39
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $9.00
AVG Volume (30 Days)
30.2K
★ 236.2K
Earning Date
11-28-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 32.56
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.46
$1.00
52 Week High
$21.30
$7.19

Technical Indicators

Market Signals
Indicator
PHOS
ANTX
Relative Strength Index (RSI) 38.03 49.94
Support Level N/A $3.89
Resistance Level $13.37 $5.11
Average True Range (ATR) 0.98 0.39
MACD -0.01 0.07
Stochastic Oscillator 1.34 45.83

Price Performance

Historical Comparison
PHOS
ANTX

About PHOS First Phosphate Corp. American Depositary Shares

First Phosphate Corp owns and is developing igneous rock phosphate mineral properties in the Saguenay Region of Quebec for the production of phosphoric acid for the production of cathode active material for use in lithium iron phosphate (LPF) batteries for the electric vehicle industry.

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

Share on Social Networks: